Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 513 of 5804
-
Triple drug cocktail targets Hard-to-Treat colorectal cancer
Disease control Recruiting nowTo learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy aims to boost remission in hodgkin lymphoma
Disease control Recruiting nowThe main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin …
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for ALS: first human trial of Gene-Targeting drug begins
Disease control Recruiting nowThis study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This …
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for tough lung cancer: tarlatamab trial targets advanced disease
Disease control OngoingThe primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can community action stop violence against women? malawi trial aims to find out
Prevention Recruiting nowViolence against women is complex and must be addressed at multiple levels, with leadership from women themselves on how to bring about positive change to free women and girls from daily experiences of violence and to promote their rights. It is in this context that the Pamodzi K…
Phase: NA • Sponsor: George Washington University • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
New drug may extend remission after CAR-T in myeloma
Disease control TerminatedThis phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment wi…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug could ease bulging eyes in thyroid disease
Disease control OngoingThis is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for hard-to-treat breast cancer: experimental combo shows promise
Disease control OngoingThis study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally ad…
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for Hard-to-Treat blood cancer: experimental drug shows promise
Disease control OngoingAll subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the dru…
Phase: PHASE2 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for asthma sufferers: dupilumab may beat higher steroid doses
Disease control OngoingThis study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms w…
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Pregnancy vaccine shields newborns from RSV: Real-World data reveals impact
⭐️ VACCINE ⭐️ OngoingThis study will be conducted in collaboration with a research network of independent hospital sites to evaluate the vaccine effectiveness (VE) and impact of ABRYSVO vaccination during pregnancy in a real-world population over multiple seasons, which began in 2024 across Argentina…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:34 UTC
-
New magnetic therapy could offer gentler depression treatment
Symptom relief Recruiting nowThe purpose of this study is to compare the efficacy and side effects magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD).
Phase: NA • Sponsor: Joao L. DeQuevedo • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
New hope for wet AMD: two novel drugs enter final testing phase
Disease control OngoingA Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Phase: PHASE3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Pedaling against Parkinson's: Exercise-Genetics trial launches
Disease control Recruiting nowThe proposed multi-site, Genetics and Aerobic Exercise to Slow PD (GEARS) Trial will, for the first time, determine the interplay between genetics and exercise in altering PD progression. In sum, 200 PD patients will be recruited from the Cleveland and Salt Lake City metro areas …
Phase: NA • Sponsor: Jay Alberts • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New pill-and-immunotherapy cocktail takes on advanced tumors
Disease control Recruiting nowThis study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be ad…
Phase: PHASE1, PHASE2 • Sponsor: 7 Hills Pharma, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Heat and immunotherapy join forces against bile duct cancer
Disease control Recruiting nowThe present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multid…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New injection aims to tame lupus when standard treatments fail
Disease control OngoingThis is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus Erythematosus (SLE).
Phase: PHASE1, PHASE2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New CAR-T therapy targets Tough-to-Treat myeloma
Disease control Recruiting nowDespite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New study pits two drug combos against stubborn thyroid cancer
Disease control Recruiting nowThis phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a c…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental triple therapy aims to tame leukemia without intensive chemo
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AML). Iadademstat inhibits the LSD1 protein and may lead to inhibition of cell gro…
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC